Webinar | An Integrated Approach To Spray Drying: From Scale-Up To Manufacturing
Date: Tuesday, November 19, 2019
Time: 10:00 AM EST
Duration: 1 hour
The use of spray drying to manufacture amorphous dispersions is continuing to grow due to the number of drug candidates exhibiting poor solubility. Nearly 40% of the new chemical entities (NCEs) screened by pharmaceutical companies fail to progress to later stages of development due to poor aqueous solubility.1 The application of a phase-appropriate quality-by-design (QbD) framework increases the understanding of the interplay between the process parameters of spray drying and product quality that, when applied during scale-up, increases the chances of a successful outcome of the commercial manufacturing process.
Key Learning Objectives:
- Determining when spray drying is the right technology for bioavailability enhancement
- The importance of process and formulation parameters that need to be addressed for successful commercial scale-up
- The importance of the optimization of process parameters; what could go wrong if not executed correctly
- How integrated services can minimize risk and save cost and time on development and manufacturing process
1Roots Analysis Business Research & Consulting, Pharmaceutical Spray Drying Market, 2nd edition 2018-2028.
Director, Engineering & Continuous Improvement
Arclight Pharmaceuticals, LLC